Aller au contenu principal
Retour à l'annuaire
📇 Rhumatologue · Boulogne-Billancourt · (92) · Mixte

Docteur ARIANE LEBOIME-GRIGAUT

Pourquoi vous devez consulter ce praticien

5 raisons identifiées

  • Plateau technique de référence

    Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes

  • Auteur de référence en rhumatologie

    50 articles scientifiques publiés — un praticien à la pointe de la recherche

  • Secteur 2 OPTAM — dépassements modérés

    Tarifs maîtrisés, mieux remboursés par votre mutuelle qu'un secteur 2 standard

  • Disponibilité géographique

    2 lieux d'exercice — choisissez celui qui vous arrange

  • Carte Vitale acceptée

    Remboursement direct par la Sécu — pas d'avance pour la part obligatoire

RhumatologueMédecins généralistes et spécialistes🏥 Libéral temps partiel hosp.
📍 Boulogne-Billancourt (92)Mixte💶 Secteur 2RPPS 10100086502

Diplômes

🎓 DES & spécialité ordinale

  • DES Rhumatologie
  • Rhumatologie (SM)

🎓 Diplômes

  • DE Docteur en médecine

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

Lieux de consultation(2)

Plan généré via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

  • GHU APHP UPS SITE AMBROISE PARE

    9 Avenue CHARLES DE GAULLE, 92104 Boulogne-Billancourt

    ☎ 0149095000Hospitalier

  • CABINET DU DR ARIANE LEBOIME-GRIGAUT

    30TER RUE DE L ANCIENNE MAIRIE, 92100 Boulogne-Billancourt

    Libéral

Tarifs & secteur de conventionnement

🟡 Secteur 2 — Honoraires libresSource CNAM (Annuaire santé Ameli)
✓ OPTAM💳 Carte VitaleLibéral temps partiel hosp.
📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib📇 Ajouter à mes contacts

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

  • 1
    Irisin ameliorates bone loss in ovariectomized mice

    Climacteric : the journal of the International Menopause Society · 2020

    📚 34 citations🎯 RCR 2.29Top 23% NIH
  • 2
    Role and Therapeutic Potential for Targeting Fibroblast Growth Factor 10/FGFR1 in Relapsed Rheumatoid Arthritis

    Arthritis & rheumatology (Hoboken, N.J.) · 2024

    📚 31 citations🎯 RCR 5.26Top 7% NIH🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    ObjectiveFibroblast‐like synoviocytes (FLSs) contribute to inflammation and joint damage in rheumatoid arthritis (RA). However, the regulatory mechanisms of FLSs in relapse and remission of RA remain unknown. Identifying FLS heterogeneity and their underlying pathogenic roles may lead to discovering novel disease‐modifying antirheumatic drugs.MethodsCombining single‐cell RNA sequencing (scRNA‐seq) and spatial transcriptomics, we sequenced six matched synovial tissue samples from three patients with relapse RA and three patients in remission. We analyzed the differences in the transcriptomes of the FLS subsets between the relapse and remitted phases. We validated several key signaling pathways using quantitative real‐time PCR (qPCR) and multiplex immunohistochemistry (mIHC). We further targeted the critical signals in vitro and in vivo using the collagen‐induced arthritis (CIA) model in rats.ResultsLining and sublining FLS subsets were identified using scRNA‐seq. Differential analyses indicated that the fibroblast growth factor (FGF) pathway was highly activated in the lining FLSs from patients with relapse RA for which mIHC confirmed the increased expression of FGF10. Although the type I interferon pathway was also activated in the lining FLSs, in vitro stimulation experiment suggested that it was independent of the FGF10 pathway. FGF10 knockdown by small interfering RNA in FLSs significantly reduced the expression of receptor activator of NF‐κB ligand. Moreover, recombinant FGF10 protein enhanced bone erosion in the primary human‐derived pannus cell culture, whereas the FGF receptor (FGFR) 1 inhibitor attenuated this process. Finally, administering an FGFR1 inhibitor displayed a therapeutic effect in a CIA rat model.ConclusionThe FGF pathway is a critical signaling pathway in relapse RA. Targeted tissue‐specific inhibition of FGF10/FGFR1 may provide new opportunities to treat patients with relapse RA.

  • 3
    The Effectiveness of Tuina in Relieving Pain, Negative Emotions, and Disability in Knee Osteoarthritis: A Randomized Controlled Trial

    Pain medicine (Malden, Mass.) · 2023

    📚 30 citations🎯 RCR 6.74Top 5% NIH🩺 Clinique
    Lire l'abstract Crossref ↓

    AbstractObjectiveTo evaluate the effectiveness of Tuina in relieving the pain, negative emotions, and disability of patients with knee osteoarthritis (KOA).DesignSingle-center, parallel, randomized controlled trial.SettingShanghai Guanghua Integrated Chinese and Western Medicine Hospital, Shanghai, China.SubjectsAdult patients with KOA who were able to speak Chinese and self-report symptoms were eligible.MethodsA total of 104 patients were randomly allocated to receive the 6-week treatment of Tuina (Tuina group) or celecoxib (celecoxib group). Data on pain, negative emotions, and disability were collected at baseline, at week 2, 4, and 6, and follow-up (1 month after the last treatment). The primary outcomes were the pressure pain thresholds. The secondary outcomes were: (1) numerical rating scale at rest and with movement; (2) Hamilton Anxiety Scale; (3) Hamilton Depression Scale; (4) Western Ontario and McMaster Universities Osteoarthritis Index; and (5) clinical effective rate. The adverse events of the trial were evaluated.ResultsIn total, 99 patients completed the follow-up. Generalized linear mixed models were constructed to analyse the between-group differences. Statistically significant differences were found in the interaction effects (P < .05). In evaluating the group effect, statistical differences were found at week 6 and follow-up (P < .05). Further, all variables showed a time effect (P < .05). A statistical difference in the clinical effective rate was found between the Tuina and celecoxib groups (P < .05).ConclusionsTuina produced superior effects for pain, negative emotions, and disability over time, as compared to celecoxib in patients with KOA.

Publications scientifiques (50) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Transversal30

▼

csDMARDs4

▼

Lupus4

▼

Case report / série2

▼

Qualité de vie / PROMs2

▼

Arthrite juvénile1

▼

Biomarqueurs / Auto-Ac1

▼

Épidémiologie & registres1

▼

Essai clinique1

▼

IRM ostéo-articulaire1

▼

Ostéoporose1

▼

Revue / méta-analyse1

▼

Revue générale1

▼

Santé mentale / fatigue1

▼

Sjögren1

▼

Vraie vie / RWE1

▼

Partager cette fiche

in LinkedIn🟢 WhatsApp✉ Email

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.